ALLEGATO A

UNIVERSITÀ DEGLI STUDI DI MILANO
Procedura di valutazione per la chiamata a professore di I fascia da ricoprire ai sensi dell'art. 24, comma 6, della Legge n. 240/2010 per il settore concorsuale 06/A4 -Anatomia Patologica ,
(settore scientifico-disciplinare MED/08 -Anatomia Patologica)
presso il Dipartimento di ONCOLOGIA ED EMATO-ONCOLOGIA, Codice concorso 3651

Giancarlo Pruneri

CURRICULUM VITAE

INFORMAZIONI PERSONALI

COGNOME	**PRUNERI**
NOME	**GIANCARLO**
DATA DI NASCITA	15 APRILE 1966

ATTIVITÀ DI RICERCA E PUBBLICAZIONI SCIENTIFICHE

Principali settori di ricerca ed interessi scientifici

L'attività di ricerca del Prof. Pruneri è principalmente rivolta a studi traslazionali sul cancro, in particolare focalizzata sui meccanismi molecolari coinvolti nella carcinogenesi e sull'identificazione di fattori predittivi e prognostici delle neoplasie mammarie, del sistema emolinfopoietico e delle neoplasie del distretto testa-collo. L'attività di ricerca è fortemente caratterizzata per la sua multidisciplinarità e flessibilità, volta ad integrare differenti esperienze in campo pre-clinico e clinico con le specifiche competenze di anatomia patologica, con un approccio rivolto al trasferimento delle scoperte scientifiche per la personalizzazione delle cure nella pratica clinica. In questo contesto, il candidato ha acquisito specifiche competenze nelle principali tecnologie utilizzate nella ricerca traslazionale (morfologia tradizionale, immunoistochimica, citofluorimetria, ibridazione in situ, western-blot, espressione genica, citogenetica, sequenziamento genico e "next-generation sequencing"), nella ricerca clinica (disegno di studi clinici, analisi biostatistiche, studi di riproducibilità) e pre-clinica (linee cellulari, modelli murini, xenografts). Il Prof. Pruneri ha svolto sia come leader che nel contesto di gruppi internazionali numerose ricerche di tipo clinico e pre-clinico. In questo contesto, il Prof. Pruneri ha maturato un'esperienza rilevante nella caratterizzazione morfologica e fenotipica delle neoplasie sviluppate in modelli murini, con particolare riferimento alle patologie del sistema emolinfopoietico e mammario.

Nel periodo della sua borsa di studio triennale all'Istituto di Anatomia Patologica dell'Ospedale Policlinico di Milano (1996-1999), sotto la guida dei Prof. Buffa e Neri, il Prof. Pruneri ha svolto studi pionieristici sulla prevalenza e rilevanza clinica delle alterazioni del ciclo cellulare nelle neoplasie del distretto testa-collo identificate con metodiche immunoistochimiche e molecolari (Pruneri, J Clin Oncol, 1999) e sull'angiogenesi nelle neoplasie del sistema emolinfopoietico, in particolare mielodisplasie (Pruneri, Br J Cancer, 1999), linfomi non-Hodgkin, mieloma plasmacellulare e leucemie acute, integrando dati ottenuti su tessuto e modelli murini NOD/SCID (Bertolini, Blood, 2000). In seguito al suo trasferimento presso la Divisione di Anatomia Patologica dell'Istituto Europeo di Oncologia (IEO) nel 1999, il Prof. Pruneri ha attivamente partecipato alla validazione della tecnica intraoperatoria del linfonodo sentinella per le pazienti con carcinoma mammario, sviluppata dal Prof. Viale (Viale, J Surg Oncol, 2004) e all'analisi del suo significato predittivo e clinico (Colleoni, JCO, 2005; Viale, Ann Surg, 2005). In IEO, la ricerca del Prof. Pruneri si è principalmente focalizzata sul carcinoma della mammella e sulle neoplasie del sistema emolinfopoietico. In stretta collaborazione con le Divisioni di Oncologia Medica e Biostatistica, il Prof. Pruneri ha contribuito all'identificazione della rilevanza clinica delle caratteristiche morfologiche e fenotipiche dei diversi sottotipi di carcinoma mammario invasivo (Colleoni, Ann Oncol, 2007 e 2012). In quest'ambito, il Prof. Pruneri ha studiato la rilevanza clinica della tipizzazione immunoistochimica del carcinoma invasivo (Maisonneuve, Breast Cancer Res, 2014), dimostrando che l'utilizzo appropriato di una tecnologia molto diffusa e non particolarmente costosa come l'immunoistochimica può garantire una corretta

caratterizzazione, e quindi un trattamento adeguato, delle pazienti con carcinoma mammario. In relazione a queste competenze scientifiche, il Prof. Pruneri è stato recentemente coinvolto in uno studio finanziato da AIRC e coordinato dal Prof. Di Fiore (Direttore della Divisione di Medicina Molecolare, IEO), che ha lo scopo di validare la rilevanza clinica di una signature di espressione genica. In collaborazione con la Divisione di Prevenzione e Genetica Oncologica diretta dai Dott. DeCensi e Bonanni, il Prof. Pruneri ha identificato i fattori predittivi di risposta alle terapia radiante ed endocrina nelle pazienti con carcinoma duttale in situ (Lazzeroni, Br J Cancer, 2013) e contribuito allo sviluppo di un modello clinico (studi di fase 0 o "window-of-opportunity trials") per analizzare l'efficacia biologica di composti potenzialmente utilizzabili in chemioprevenzione, come la Metformina (Bonanni, JCO, 2013). Il Prof. Pruneri ha inoltre investigato i meccanismi molecolari di specifici settings clinici di carcinoma mammario, neoplasie rare ma di grande impatto sociale come i tumori in gravidanza (Hazim, Breast Cancer Res, 2015) e nel paziente di sesso maschile (Iorfida, Clin Breast Cancer, 2014). Gli studi sul carcinoma mammario maschile sono stati sviluppati anche nel contesto di un team internazionale multidisciplinare promosso dalle Divisioni Cancer Epidemiology and Genetics and Cancer Treatment and Diagnosis del National Cancer Institute in Bethesda (US) (Korde, JCO, 2010). Recentemente, l'interesse del Prof. Pruneri si è concentrato sui meccanismi di resistenza delle neoplasie mammarie estrogeno-positive al trattamento endocrino: una recente ricerca svolta in collaborazione con i gruppi del Prof. Minucci (IEO/IFOM) e del Dott. Magnani (Imperial College, London, UK), ha dimostrato che il 21% delle pazienti con carcinoma mammario trattate con esclusiva terapia endocrina con inibitori dell'aromatasi acquisisce un'amplificazione del gene dell'aromatasi CYP19A1, che contribuisce a promuovere una stimolazione autocrina estrogenica e una conseguente resistenza alla terapia endocrina (Magnani, Nat Genet, 2017). Questo studio ha suscitato un grande interesse nella comunità scientifica e nella società, come testimoniato da numerosi interventi della stampa. Un ulteriore studio multicentrico retrospettivo e prospettico, basato su tessuti di pazienti con carcinoma mammario in cura presso IEO, disegnato per validare i dati ottenuti nel lavoro di Nat Genet è stato recentemente finanziato da AIRC nel 2016. In seguito al suo trasferimento presso la Fondazione IRCCS Istituto Nazionale dei Tumori, dove dirige dall'Agosto 2017 la Struttura Complessa di Anatomia Patologica 2, cui afferiscono più di 60 collaboratori professionali, inclusi amministrativi, tecnici di laboratorio, biotecnologi, biologi e medici, il Prof. Pruneri è stato nominato dalla Direzione Scientifica Responsabile Working Group nell'ambito dei consorzi "Alleanza contro il Cancro (ACC)" e "Cancer Core Europe (CCE)" per il suo profilo scientifico fortemente caratterizzato in senso multidisciplinare.

Principali collaborazioni

IFOM-IEO Campus

Chromatin alterations in tumorigenesis Unit (Prof. Minucci)

- Studio in vitro di meccanismi oncogenetici potenzialmente "actionable" delle leucemie acute e delle sindromi mieloproliferative, in particolare: identificazione di meccanismi di inattivazione del gene p53 in leucemie umane (Insinga, EMBO J, 2004). Studio dei meccanismi oncogenetici potenzialmente "actionable" della leucemia promielocitica (Occhionorelli, Leukemia, 2011). Identificazione di un nuovo gene di fusione, FGFR1OP-RET, come evento patogenetico delle sindromi mieloproliferative (Mol Oncol, 2014).

Nuclear proteomics for investigating multi-layered gene expression regulation Unit (Direttore Dott.ssa T. Bonaldi)

- Identificazione delle modificazioni istoniche post-traslazionali con metodichei spettrometriche (PATH-H-MS) in tessuti di archivio di carcinoma mammario (Noberini, Mol Cell Proteomics, 2016).

IFOM Istituto FIRC di Oncologia Molecolare (Prof. Pelicci)

- Identificazione delle mutazioni del gene nucleophosmin 1 (NPM1) nella patogenesi delle leucemie acute (Mallardo, Leukemia, 2013) e validazione di un marcatore immunoistochimico utile ad identificare le forme mutate del gene in tessuti di archivio (Gruszka, Blood, 2010).

Department of Surgery and Cancer Imperial College ICTEM, Hammersmith Hospital (Dott. L. Magnani)

- Studio dei meccanismi di endocrinoresistenza nelle pazienti con carcinoma mammario ER-positivo (Faronato, Oncotarget, 2015; Magnani, Nat Genet, 2017).

European Molecular Biology Laboratory (EMBL), Heidelberg, Germany (Dott. Koehler)

- Sviluppo di un metodo originale per la produzione di proteine ricombinanti in tessuti umani (Koehler, Nat Methods, 2016).

Breast Cancer Translational Research Laboratory Institut Jules Bordet, Brussels (Dott. Sotiriou)

- Caratterizzazione del carcinoma lobulare invasivo della mammella (Desmedt, JCO, 2016) con metodiche morfologiche, fenotipiche e di next-generation sequencing.

Partecipazione a gruppi di studio internazionali

- International Breast Cancer Study Group (IBCSG)
- International Extranodal Lymphoma Study Group (IELSG) (Sammassimo, Hematol Oncol, 2016)
- International Immuno-Oncology Biomarker Working Group on Breast Cancer (TILs WG) (Salgado, Ann Oncol, 2015)
- Co-chair del Translational Research Working Group (TRWG), che promuove la ricerca traslazionale all'interno dell'IBCSG (Pruneri, Breast Cancer Res Treatm, 2016)
- Core Faculty, European School of Oncology

Partecipazione a studi clinici internazionali

- Contributo alla revisione patologica centralizzata dello studio "Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) Trial, sotto la guida Prof. Viale.
- Membro del TransALTTO Committee, che promuove studi traslazionali per la valutazione di fattori predittivi e prognostici nelle pazienti con carcinoma mammario HER2 positivo incluse nello studio clinico "Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) Trial".
- Contributo allo studio clinico "Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy (MINDACT) clinical trial" (Mook, Breast Cancer Res Treatm, 2009; Mook, Eur J Cancer, 2009).
- Membro del Molecular Advisory Board dello studio AURORA (Aiming to UndeRstand the mOlecular abeRrations in metAstatic breast cancer), Breast International Group, coordinatrice Prof.ssa Martine Piccart Gebbart.
- Panelist dell'International Consensus for Breast Cancer in Young Women (BCY) (Paluch-Shimon, Breast, 2017) (Chair, Dott.ssa Pagani).

Partecipazione ad attività di divulgazione scientifica

- Specialty Editor, Pathology, "The Breast"
- Attività di revisore per numerose riviste scientifiche, per esempio Journal of Clinical Oncology, British Journal of Cancer, European Journal of Cancer, BMC, Oncotarget e Blood. Attività didattica, di didattica integrative e di servizio agli studenti

ATTIVITÀ DIDATTICA, DI DIDATTICA INTEGRATIVA E DI SERVIZIO AGLI STUDENTI

- 2004-2017 Attività didattica nell'ambito del Corso di Anatomia Patologica coordinato dal Prof. Viale per gli Studenti di Medicina del Corso di Laurea in Medicina e Chirurgia, presso il Polo San Donato, con relative commissioni di esame.
- 2012-2017 Titolare del corso di Anatomia Patologica per gli Studenti del Corso di Laurea in Fisioterapia presso il Polo Universitario San Paolo, studenti afferenti agli Ospedali San Paolo e Gaetano Pini.
- 2005-2008 Attività didattica come titolare del corso "Diagnostica dei Linfomi Maligni" per gli studenti della Scuola di Specializzazione di Anatomia Patologica.
- 2004-2017 Attività di formazione degli Studenti Frequentatori presso IEO, con elaborazione delle tesi di laurea. Partecipazione quotidiana alla discussione delle problematiche istopatologiche e molecolari relative ai casi clinici con i Medici Specializzandi della Scuola di Anatomia Patologica. Referente nell'impostazione e nella stesure delle tesi di specializzazione.
- 2015-2017 Docente e componente del collegio didattico del Corso di laurea Magistrale in Medical Biotechnology and Molecular Medicine (Head of Studies Diego Fornasari).

ATTIVITÀ ISTITUZIONALE UNIVERSITARIA

- 2015 - Membro del Dipartimento di Oncologia ed Emato-Oncologia dell'Università degli Studi di Milano.
- 2016 – Responsabile designato all'Internazionalizzazione del Dipartimento di Oncologia ed Emato-Oncologia.
- 2016 – Collaborazione attiva alle attività del progetto Erasmus
- 2016 – Membro della Giunta del Dipartimento di Oncologia ed Emato-Oncologia.
- 2017 – Referente dell'Università di Milano del progetto di partnership tra UNIMI, Bologna IN e Manipal University (India), promosso dal Programma Erasmus+ dell'Unità Europea.

TITOLI DI STUDIO

- Laureato in Medicina e Chirurgia presso l'Università degli Studi di Milano, il 15.10.1992 (110/110 e lode).
- Diplomato Specialista in Anatomia e Istologia Patologica presso l'Università degli Studi di Milano il 12.11.1996 (70/70 e lode).

ATTIVITÀ CLINICO-ASSISTENZIALE

- 1999-2017 Attività assistenziale presso la Divisione di Anatomia Patologica e Medicina di Laboratorio dell'Istituto Europeo di Oncologia, con la qualifica di Assistente negli anni 1999-2003, Assistente senior negli anni 2003-2007, Vice Direttore negli anni 2007-2011, e Vice Direttore Senior dall'anno 2011.
- 1999-2017 Refertazione di circa 40.000 esami istologici (comprensivi di consulenze istopatologiche), 8.000 esami intra-operatori, 2.000 esami citologici e 2.000 esami molecolari.
- 2000-2015 Referente della Divisione di Anatomia Patologica IEO per la Diagnostica Istopatologica delle Neoplasie del Sistema Emolinfopoietico. Sviluppo di una procedura diagnostica innovativa, in collaborazione con la Divisione di Radiologia Interventistica, basata su materiale prelevato esclusivamente con agobiopsia da sedi superficiali e profonde (comprese le lesioni mediastiniche), per la caratterizzazione completa della malattia evitando la resezione chirurgica delle relative lesioni.
- 1999-2017 Attività quotidiana di tutoraggio e supervisione per i Medici Assistenti in IEO
- 1999-2017 Partecipazione alle riunioni inter-disciplinari periodiche, in particolare con le Divisioni di Emato-Oncologia, Senologia e Ginecologia IEO.
- 2005-2017 Membro attivo del board dei Programmi IEO Ginecologia (Chair Prof.ssa N. Colombo) e "Drug Discovery" (Co-chairs Prof. Saverio Minucci e Dott. Giuseppe Curigliano).
- 2017, I Agosto Responsabile della Struttura Complessa di Anatomia Patologica 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.

CARRIERA OSPEDALIERA ED UNIVERSITARIA

- 1996-1999 Borsista Medico presso il II Servizio di Anatomia Patologica, Ospedale Maggiore Policlinico di Milano.
- 1999-2003 Assistente Medico presso il Laboratorio di Anatomia Patologica e Medicina di Laboratorio, Istituto Europeo di Oncologia, Milano.
- 2003-2007 Assistente Medico Senior presso il Laboratorio di Anatomia Patologica e Medicina di Laboratorio, Istituto Europeo di Oncologia, Milano.

- 2004 Vincitore Concorso di Ricercatore presso l'Università degli studi di Milano.
- 2005-2015 Ricercatore Universitario convenzionato presso l'Istituto Europeo di Oncologia.
- 2007-2011 Vice Direttore presso il Laboratorio di Anatomia Patologica e Medicina di Laboratorio, Istituto Europeo di Oncologia, Milano.
- 2011-2015 Vice Direttore Senior presso il Laboratorio di Anatomia Patologica e Medicina di Laboratorio, Istituto Europeo di Oncologia, Milano.
- 2015-2017 Direttore Unità di Biobanca per la Medicina Translazionale, Dipartimento di Patologia, Istituto Europeo di Oncologia, Milano.
- 2015 Professore Associato di Anatomia Patologica presso l'Università degli Studi di Milano.
- 2017 Direttore Struttura Complessa di Anatomia Patologica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

FONDI PER LA RICERCA SCIENTIFICA

Il Prof. Pruneri ha collaborato attivamente alla progettazione e realizzazione di studi di ricerca sostenuti da enti pubblici, organizzazioni scientifiche nazionali ed internazionali e da aziende private, come dettagliato nella tabella seguente:

Grant	**Periodo**	**Agenzia**	**Titolo**
MINSAL-GIOVRIC07-IFOM-PRUNERI	2007-2010	Ministero della Salute	The role of Polycomb group proteins in oncogenesys and cell reprogramming.
MINSAL-TRANSCAN-11-GC-PRUNERI	2013-2016	Ministero della Salute	CD3 and CD20 lymphocytes infiltration predict chemosensitivity in patients with triple negative breast cancer.
IEO/MYRIAD GENETICS	2012-2014	Research agreement	Evaluation of the CCP score as prognostic and predictive marker in ductal intraepithelial neoplasia
IEO/MYRIAD GENETICS	2014-2016	Research agreement	Prognostic study in estrogen receptor positive, operable breast cancer
Ontario Institute of Cancer Research (Dr. Bartlett)	2014-2016	Research agreement	Molecular progress in DCIS
AIRC 5X1000	2017-2018	AIRC	Clinical validation of a stem cell-based prognostic tool StemPrintER for the personalized management of breast cancer
AIRC IG.2016-18696:	2016-2018	AIRC	Unveiling potentially actionable mechanisms of acquired endocrine resistance in breast cancer patients

Elenco completo delle pubblicazioni

Il Prof. Pruneri ha pubblicato 245 lavori scientifici in extenso, corrispondenti a un Impact Factor complessivo superiore a 1,000 e ad un H-index di 54.

1. Criscitiello C, Bagnardi V, **Pruneri G**, Vingiani A, Esposito A, Rotmenz N, Curigliano G. Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast Cancer. Eur J Cancer. 2017;87:164-171.
2. Criscitiello C, Bayar MA, Curigliano G, Symmans FW, Desmedt C, Bonnefoi H, Sinn B, **Pruneri G**, Vicier C, Pierga JY, Denkert C, Loibl S, Sotiriou C, Michiels S, Aldré F. A gene signature to predict high-tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer. Ann Oncol. 2017 Oct 25 [Epub ahead of print]
3. Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, **Pruneri G**, D'Alfonso TM, Demaria S, Castaneda C, Sanchez J, Badve S, Michiels S, Bossuyt V, Rojo F, Singh B, Nielsen T, Viale G, Kim SR, Hewitt S, Wienert S, Loibl S, Rimm D, Symmans F, Denkert C, Adams S, Loi S, Salgado R. International Immuno-Oncology Biomarker Working Group on Breast Cancer. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol. 2017 Oct 9 [Epub ahead of print]
4. Paluch-Shimon S, Pagani O, Partridge AH, Abulkhair O, Cardoso MJ, Dent RA, Gelmon K, Gentilini O, Harbeck N, Margulies A, Meirow D, **Pruneri G**, Senkus E, Spanic T, Sutliff M, Travado L, Peccatori F, Cardoso F. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast. 2017;35:203-217
5. Gerboth S, Frittoli E, Palamidessi A, Baltanas FC, Salek M, Rappsilber J, Giuliani C, Troglio F, Rolland Y, **Pruneri G**, Kreutmair S, Pallavicini I, Zobel M, Cinquanta M, Minucci S, Gomez C, Santos E, Illert AL, Scita G. Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis. Leukemia. 2017 Aug 18 [Epub ahead of print]
6. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, **Pruneri G**, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol. 2017;24(6):311-335
7. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, **Pruneri G**, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol. 2017;24(5):235-251

8. Richichi C, Fornasari L, Melloni GEM, Brescia P, Patanè M, Del Bene M, Mustafa DAM, Kros JM, Pollo B, **Pruneri G**, Sciandivasci A, Munzone E, DiMeco F, Pelicci PG, Riva L, Pelicci G. Mutations targeting the coagulation pathway are enriched in brain metastases. Sci Rep. 2017;7(1):6573
9. Noberini R, Longuespée R, Richichi C, **Pruneri G**, Kriegsmann M, Pelicci G, Bonaldi T. PAT-H-MS coupled with laser microdissection to study histone post-translational modifications in selected cell populations from pathology samples. Clin Epigenetics. 2017 Jul 11;9:69.
10. Magnani L, Frigè G, Gadaleta RM, Corleone G, Fabris S, Kempe MH, Vershure PJ, Barozzi I, Vircillo V, Hong SP, Perone Y, Saini M, Trumpp A, Viale G, Neri A, Ali S, Colleoni MA, **Pruneri G**, Minucci S. Corrigendum: Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer. Nat Genet. 2017;49(6):970
11. Montagna E, Vingiani A, Maisonneuve P, Cancello G, Contaldo F, **Pruneri G**, Colleoni M. Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. Breast. 2017;34:83-88
12. Havas KM, Milchevskaya V, Radic K, Alladin A, Kafkia E, Garcia M, Stolte J, Klaus B, Rotmensz N, Gibson TJ, Burwinkel B, Schneeweiss A, **Pruneri G**, Patil KR, Sotillo R, Jechlinger M. Metabolic shifts in residual breast cancer drive tumor recurrence. J Clin Invest. 2017;127(6):2091-2105
13. **Pruneri G**, Lazzeroni M, Bagnardi V, Tiburzio GB, Rotmensz N, DeCensi A, Guerrieri-Gonzaga A, Vingiani A, Curigliano G, Zurrida S, Bassi F, Salgado R, Van den Eynden G, Loi S, Denkert C, Bonanni B, Viale G. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Ann Oncol. 2017;28(2):321-328
14. Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D, Cazzaniga M, Aristarco V, Macis D, Mora S, Caldarella P, Pagani G, **Pruneri G**, Riva A, Petrangolini G, Morazzoni P, DeCensi A, Bonanni B.A. Presurgical Study of Lecithin Formulation of Green Tea Extract in Women with Early Breast Cancer. Cancer Prev Res (Phila). 2017;10(6):363-370
15. **Pruneri G**, Vingiani A, Denkert C. Tumor infiltrating lymphocytes in early breast cancer. Breast. 2017 Mar 28 [Epub ahead of print]
16. Tosoni D, Pambianco S, Ekalle Soppo B, Zecchini S, Bertalot G, **Pruneri G**, Viale G, Di Fiore PP, Pece S. Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers. EMBO Mol Med. 2017 May;9(5):655-671
17. Lazzeroni M, Dunn BK, **Pruneri G**, Jereczek-Fossa BA, Orecchia R, Bonanni B, DeCensi A. Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora's box. Cancer Treat Rev. 2017;55:1-9
18. Curigliano G, Criscitiello C, Esposito A, **Pruneri G**. Over-using chemotherapy in the adjuvant setting. Breast. 2017;31:303-308.
19. Koehler C, Sauter PF, Wawryszyn M, Girona GE, Gupta K, Landry JJ, Fritz MH, Radic K, Hoffmann JE, Chen ZA, Zou J, Tan PS, Galik B, Junttila S, Stolt-Bergner P, **Pruneri G**, Gyenesei A, Schultz C, Biskup MB, Besir H, Benes V, Rappsilber J, Jechlinger M, Korbel JO, Berger I, Braese S, Lemke EA. Genetic code expansion for multiprotein complex engineering. Nat Methods. 2016;13(12):997-1000.
20. D'Alesio C, Punzi S, Cicalese A, Fornasari L, Furia L, Riva L, Carugo A, Curigliano G, Criscitiello C, **Pruneri G**, Pelicci PG, Faretta M, Bossi D, Lanfrancone L. RNAi screens identify CHD4 as an essential gene in breast cancer growth.Oncotarget. 2016;49(7):80901-80915.
21. **Pruneri G**, Bonizzi G, Vingiani A. Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients. Curr Opin Oncol. 2016;28(6):476-483.
22. Noberini R, **Pruneri G**, Minucci S, Bonaldi T. Mass-spectrometry analysis of histone post-translational modifications in pathology tissue using the PAT-H-MSapproach. Data Brief. 2016;7:188-94.
23. Guerrieri-Gonzaga A, Sestak I, Lazzeroni M, Serrano D, Rotmensz N, Cazzaniga M, Varricchio C, **Pruneri G**, Leonardi MC, Orecchia R, Galimberti V, Bonanni B, DeCensi A. Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS. Int J Cancer. 2016;139(9):2127-34.
24. **Pruneri G**, Gray KP, Vingiani A, Viale G, Curigliano G, Criscitiello C, Láng I,Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Cancello G, Munzone E,Gelber RD, Regan MM, Colleoni M. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Res Treat. 2016;158(2):323-31.
25. Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, Bane A, Bedri S, Brock J, Chmielik E, Christgen M, Colpaert C, Demaria S, Van den Eynden G, Floris G, Fox SB, Gao D, Ingold Heppner B, Kim SR, Kos Z, Kreipe HH, Lakhani SR, Penault-Llorca F, **Pruneri G**, Radosevic-Robin N, Rimm DL, Schnitt SJ, Sinn BV, Sinn P, Sirtaine N, O'Toole SA, Viale G, Van de Vijver K, de Wind R, von Minckwitz G, Klauschen F, Untch M, Fasching PA, Reimer T, Willard-Gallo K, Michiels S, Loi S, Salgado R. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol. 2016;29(10):1155-64.
26. Aurilio G, Sandri MT, **Pruneri G**, Zorzino L, Botteri E, Munzone E, Adamoli L, Facchi G, Cullurà D, Verri E, Rocca MC, Zurrida S, Iacovelli R, Nolè F. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer. Future Oncol. 2016;12(17):2001-8.

27. Aristarco V, Serrano D, Gandini S, Johansson H, Macis D, Guerrieri-Gonzaga A, Lazzeroni M, Feroce I, **Pruneri G**, Pagani G, Toesca A, Caldarella P, DeCensi A, Bonanni B. A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients. Cancer Prev Res (Phila). 2016;9(5):349-56.
28. Desmedt C, Zoppoli G, Gundem G, **Pruneri G**, Larsimont D, Fornili M, Fumagalli D, Brown D, Rothé F, Vincent D, Kheddoumi N, Rouas G, Majjaj S, Brohée S, Van Loo P, Maisonneuve P, Salgado R, Van Brussel T, Lambrechts D, Bose R, Metzger O, Galant C, Bertucci F, Piccart-Gebhart M, Viale G, Biganzoli E, Campbell PJ, Sotiriou C. Genomic Characterization of Primary Invasive Lobular Breast Cancer. J Clin Oncol. 2016;34(16):1872-81.
29. Signaroldi E, Laise P, Cristofanon S, Brancaccio A, Reisoli E, Atashpaz S, Terreni MR, Doglioni C, **Pruneri G**, Malatesta P, Testa G. Polycomb dysregulation in gliomagenesis targets a Zfp423-dependent differentiation network. Nat Commun. 2016;7:10753.
30. **Pruneri G**, Vingiani A, Bagnardi V, Rotmensz N, De Rose A, Palazzo A, Colleoni AM, Goldhirsch A, Viale G. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. Ann Oncol. 2016;27(2):249-56.
31. Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D, Cazzaniga M, Aristarco V, Puccio A, Mora S, Caldarella P, Pagani G, **Pruneri G**, Riva A, Petrangolini G, Morazzoni P, DeCensi A, Bonanni B. A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer. CancerPrev Res (Phila). 2016;9(1):89-95.
32. Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, **Pruneri G**, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Ann Oncol. 2015;26(12):2505-6.
33. Noberini R, Uggetti A, **Pruneri G**, Minucci S, Bonaldi T. Pathology Tissue-quantitative Mass Spectrometry Analysis to Profile Histone Post-translational Modification Patterns in Patient Samples. Mol Cell Proteomics. 2016;15(3):866-77.
34. Aurilio G, Gori S, Nolè F, **Pruneri G**, Coati F, Torri V, Lunardi G, Atzori F, La Verde N, Banna GL, Rossi A, Del Mastro L, Di Fabio F, Marcon I, Gebbia V, Loupakis F, Orlando L, Ciuffreda L, Amadio P, Luppi G, Redana S, Filippelli G, Gentile A, Collovà E. Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology. Tumori. 2016;102(1):108-13.
35. Sammassimo S, **Pruneri G**, Andreola G, Montoro J, Steffanoni S, Nowakowski GS, Gandini S, Negri M, Habermann TM, Raderer M, Li ZM, Zinzani PL, Adam P, Zucca E, Martinelli G. A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG). Hematol Oncol. 2016;34(4):177-83.
36. Gruszka AM, Rabascio C, Cannella L, Sammassimo S, Andreola G, Gregato G, Faretta M, Calleri A, De Molfetta R, **Pruneri G**, Bertolini F, Alcalay M. Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma - a case report. Sci Rep. 2015;5:14829.
37. DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Lazzeroni M, Vingiani A, Gentilini O, Petrera M, Viale G, Cuzick J, Bonanni B, **Pruneri G**. Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial. Cancer Prev Res (Phila). 2015;8(10):888-94.
38. Faronato M, Nguyen VT, Patten DK, Lombardo Y, Steel JH, Patel N, Woodley L, Shousha S, **Pruneri G**, Coombes RC, Magnani L. DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation. Oncotarget. 2015;6(26):22467-79.
39. Aurilio G, Bagnardi V, Nolè F, **Pruneri G**, Graffeo R, Petit JY, Cullurà D, Martella S, Locatelli M, Iera M, Rey P, Curigliano G, Rotmensz N, Munzone E, Goldhirsch A. Outcome of Immediate Breast Reconstruction in Patients With Nonendocrine-Responsive Breast Cancer: A Monoinstitutional Case-Control Study. Clin Breast Cancer. 2015 Oct;15(5):e237-41.
40. Chiaradonna F, Barozzi I, Miccolo C, Bucci G, Palorini R, Fornasari L, Botrugno OA, **Pruneri G**, Masullo M, Passafaro A, Galimberti VE, Fantin VR, Richon VM, Pece S, Viale G, Di Fiore PP, Draetta G, Pelicci PG, Minucci S, Chiocca S. Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer. Antioxid Redox Signal. 2015;23(1):15-29.
41. Azim HA Jr, Peccatori FA, Brohée S, Branstetter D, Loi S, Viale G, Piccart M, Dougall WC, **Pruneri G**, Sotiriou C. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res. 2015;21;17:24.
42. Azim HA Jr, Vingiani A, Peccatori F, Viale G, Loi S, **Pruneri G**. Tumourinfiltrating lymphocytes (TILs) in breast cancer during pregnancy. Breast 2015;24(3):290-3.

43. Curigliano G, Disalvatore D, Esposito A, **Pruneri G**, Lazzeroni M,Guerrieri-Gonzaga A, Luini A, Orecchia R, Goldhirsch A, Rotmensz N, Bonanni B, Viale G. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. Ann Oncol. 2015;26(4):682-7.
44. Adamo A, Atashpaz S, Germain PL, Zanella M, D'Agostino G, Albertin V, Chenoweth J, Micale L, Fusco C, Unger C, Augello B, Palumbo O, Hamilton B, Carella M, Donti E, **Pruneri G**, Selicorni A, Biamino E, Prontera P, McKay R, Merla G, Testa G. 7q11.23 dosage-dependent dysregulation in human pluripotent stem cells affects transcriptional programs in disease-relevant lineages. Nat Genet. 2015;47(2):132-41.
45. DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, **Pruneri G**, Serrano D, Schwab M, Hofmann U, Mora S, Aristarco V, Macis D, Bassi F, Luini A, Lazzeroni M, Bonanni B, Pollak MN. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat. 2014;148(1):81-90.
46. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, **Pruneri G**, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S. International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259-71.
47. Martinelli G, Montoro J, Vanazzi A, Andreola G, Liptrott S, Radice D, Negri M, Preda L, **Pruneri G**, Laszlo D. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study. Hematol Oncol. 2015 Dec;33(4):129-35.
48. Munzone E, Bagnardi V, Rotmensz N, Sporchia A, Mazza M, **Pruneri G**, Intra M, Sciandivasci A, Gentilini O, Luini A, Viale G, Veronesi P, Colleoni M. Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer. Breast Cancer Res Treat. 2014 Aug;146(3):573-82.
49. **Pruneri G**, Gigli F, Rafaniello Raviele P, Gardellini A, Raimondi S, De Fiori E, Preda L, Viale G, Martinelli G, Laszlo D. Core needle biopsy as a front line diagnostic approach for lymphoma patients. Hematol Oncol. 2015;33(4):247-9.
50. Maisonneuve P, Disalvatore D, Rotmensz N, Curigliano G, Colleoni M, Dellapasqua S, **Pruneri G**, Mastropasqua MG, Luini A, Bassi F, Pagani G, Viale G, Goldhirsch A. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res. 2014;16(3):R65.
51. Azim HA Jr, Brohée S, Peccatori FA, Desmedt C, Loi S, Lambrechts D, Dell'Orto P, Majjaj S, Jose V, Rotmensz N, Ignatiadis M, **Pruneri G**, Piccart M, Viale G, Sotiriou C. Biology of breast cancer during pregnancy using genomic profiling. Endocr Relat Cancer. 2014;21(4):545-54.
52. Meroni S, Bozzini AC, **Pruneri G**, Moscovici OC, Maisonneuve P, Menna S, Penco S, Meneghetti L, Renne G, Cassano E. Underestimation rate of lobular intraepithelial neoplasia in vacuum-assisted breast biopsy. Eur Radiol. 2014;24(7):1651-8.
53. Iorfida M, Bagnardi V, Rotmensz N, Munzone E, Bonanni B, Viale G, **Pruneri G**, Mazza M, Cardillo A, Veronesi P, Luini A, Galimberti V, Goldhirsch A, Colleoni M. Outcome of male breast cancer: a matched single-institution series. Clin Breast Cancer. 2014;14(5):371-7.
54. Aurilio G, Graffeo R, Bagnardi V, Nolè F, Adamoli L, Pagani O, Gallerani E, Ferrari B, **Pruneri G**, Goldhirsch A. Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case series. Int J Clin Oncol. 2015;20(1):90-4.
55. Fumagalli C, Della Pasqua S, Bagnardi V, Cardillo A, Sporchia A, Colleoni M, Viale G, Barberis M, **Pruneri G**. Prevalence and clinicopathologic correlates of O^6-methylguanine-DNA methyltransferase methylation status in patients with triple-negative breast cancer treated preoperatively by alkylating drugs. Clin Breast Cancer. 2014;14(4):285-90..
56. Toffalorio F, Belloni E, Barberis M, Bucci G, Tizzoni L, **Pruneri G**, Fumagalli C, Spitaleri G, Catania C, Melotti F, Pelicci PG, Spaggiari L, De Pas T. Gene expression profiling reveals GC and CEACAM1 as new tools in the diagnosis of lung carcinoids. Br J Cancer. 2014;110(5):1244-9.
57. Aurilio G, Nolè F, Viale G, **Pruneri G**. Reply to letter by Ieni et al. Eur J Cancer. 2014;50(5):1038-9.
58. Maffini F, Cocorocchio E, **Pruneri G**, Bonomo G, Peccatori F, Chiapparini L, Vincenzo SD, Martinelli G, Viale G. Locked-in syndrome after basilary artery thrombosis by mucormycosis masquerading as meningoencephalitis in a lymphoma patient. Ecancermedicalscience. 2013;19:7:382.
59. Adam P, Czapiewski P, Colak S, Kosmidis P, Tousseyn T, Sagaert X, Boudova L, Okoń K, Morresi-Hauf A, Agostinelli C, Pileri S, **Pruneri G**, Martinelli G, Du MQ, Fend F. Prevalence of Achromobacter xylosoxidans in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe. Br J Haematol. 2014;164(6):804-10.
60. Gandini S, Guerrieri-Gonzaga A, **Pruneri G**, Serrano D, Cazzaniga M, Lazzeroni M, Veronesi P, Johansson H, Bonanni B, Viale G, Decensi A. Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials. Ann Oncol. 2014;25(3):618-23.

61. Balduzzi A, Bagnardi V, Rotmensz N, Dellapasqua S, Montagna E, Cardillo A, Viale G, Veronesi P, Intra M, Luini A, **Pruneri G**, Mastropasqua G, Goldhirsch A, Colleoni M. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression. Clin Breast Cancer. 2014;14(4):258-64.
62. Bossi D, Carlomagno F, Pallavicini I, **Pruneri G**, Trubia M, Raviele PR, Marinelli A, Anaganti S, Cox MC, Viale G, Santoro M, Di Fiore PP, Minucci S. Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies. Mol Oncol. 2014;8(2):221-31.
63. Aurilio G, Disalvatore D, **Pruneri G**, Bagnardi V, Viale G, Curigliano G, Adamoli L, Munzone E, Sciandivasci A, De Vita F, Goldhirsch A, Nolè F. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer. 2014;50(2):277-89.
64. Maffini F, Renne G, Olivadese R, Solli P, Locatelli M, **Pruneri G**, Barberis M, Viale G. A rare case of lung metastasis from a malignant adenomyoepithelioma of the breast: histological features and therapeutic implications. Ecancermedicalscience. 2013; 12;7:372
65. Cazzaniga M, DeCensi A, **Pruneri G**, Puntoni M, Bottiglieri L, Varricchio C, Guerrieri-Gonzaga A, Gentilini OD, Pagani G, Dell'Orto P, Lazzeroni M, Serrano D, Viale G, Bonanni B. The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer. 2013;109(11):2792-7.
66. Cancello G, Maisonneuve P, Mazza M, Montagna E, Rotmensz N, Viale G, **Pruneri G**, Veronesi P, Luini A, Gentilini O, Goldhirsch A, Colleoni M. Pathological features and survival outcomes of very young patients with early breast cancer: how much is "very young"? Breast. 2013;22(6):1046-51.
67. Orecchioni S, Gregato G, Martin-Padura I, Reggiani F, Braidotti P, Mancuso P, Calleri A, Quarna J, Marighetti P, Aldeni C, **Pruneri G**, Martella S, Manconi A, Petit JY, Rietjens M, Bertolini F. Complementary populations of human adipose CD34+ progenitor cells promote growth, angiogenesis, and metastasis of breast cancer. Cancer Res. 2013;73(19):5880-91.
68. Lohsiriwat V, Peccatori FA, Martella S, Azim HA Jr, Sarno MA, Galimberti V, De Lorenzi F, Intra M, Sangalli C, Rotmensz N, **Pruneri G**, Renne G, Schorr MC, Nevola Teixeira LF, Rietjens M, Giroda M, Gentilini O. Immediate breast reconstruction with expander in pregnant breast cancer patients. Breast. 2013;22(5):657-60.
69. Serrano D, Lazzeroni M, Gandini S, Macis D, Johansson H, Gjerde J, Lien E, Feroce I, **Pruneri G**, Sandri M, Bassi F, Brenelli F, Luini A, Cazzaniga M, Varricchio C, Guerrieri-Gonzaga A, DeCensi A, Bonanni B. A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res. 2013;15(3):R47.
70. Vingiani A, Maisonneuve P, Dell'orto P, Farante G, Rotmensz N, Lissidini G, Del Castillo A, Renne G, Luini A, Colleoni M, Viale G, **Pruneri G**. The clinical relevance of micropapillary carcinoma of the breast: a case-control study. Histopathology. 2013;63(2):217-24.
71. Vanazzi A, Grana C, Crosta C, **Pruneri G**, Rizzo S, Radice D, Pinto A, Calabrese L, Paganelli G, Martinelli G. Efficacy of ^{90}Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma. Hematol Oncol. 2014;32(1):10-5.
72. Mallardo M, Caronno A, **Pruneri G**, Raviele PR, Viale A, Pelicci PG, Colombo E. NPMc+ and FLT3_ITD mutations cooperate in inducing acute leukaemia in a novel mouse model. Leukemia. 2013;27(11):2248-51.
73. Lazzeroni M, Guerrieri-Gonzaga A, Botteri E, Leonardi MC, Rotmensz N, Serrano D, Varricchio C, Disalvatore D, Del Castillo A, Bassi F, Pagani G, DeCensi A, Viale G, Bonanni B, **Pruneri G**. Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype. Br J Cancer. 2013;108(8):1593-601.
74. Guerrieri-Gonzaga A, Lazzeroni M, Botteri E, Serrano D, Rotmensz N, Varricchio MC, Cazzaniga M, Bollani G, Mora S, Montefrancesco C, **Pruneri G**, Viale G, Intra M, Galimberti V, Goldhirsch A, Bagnardi V, Bonanni B, DeCensi A. Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study. Ann Oncol. 2013;24(7):1859-66.
75. Fragola G, Germain PL, Laise P, Cuomo A, Blasimme A, Gross F, Signaroldi E, Bucci G, Sommer C, **Pruneri G**, Mazzarol G, Bonaldi T, Mostoslavsky G, Casola S, Testa G. Cell reprogramming requires silencing of a core subset of polycomb targets. PLoS Genet. 2013;9(2):e1003292.
76. Saghatchian M, Mook S, **Pruneri G**, Viale G, Glas AM, Guerin S, Cardoso F, Piccart M, Tursz T, Delaloge S, van't Veer L. Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes. Breast. 2013;22(5):682-90..
77. Aurilio G, Monfardini L, Rizzo S, Sciandivasci A, Preda L, Bagnardi V, Disalvatore D, **Pruneri G**, Munzone E, Della Vigna P, Renne G, Bellomi M, Curigliano G, Goldhirsch A, Nolè F. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. Acta Oncol. 2013;52(8):1649-56.
78. Dellapasqua S, Maisonneuve P, Viale G, **Pruneri G**, Mazzarol G, Ghisini R,Mazza M, Iorfida M, Rotmensz N, Veronesi P, Luini A, Goldhirsch A, Colleoni M. Immunohistochemically defined subtypes and outcome of apocrine breast cancer. Clin Breast Cancer. 2013;13(2):95-102.

79. Martin-Padura I, Marighetti P, Gregato G, Agliano A, Malazzi O, Mancuso P, **Pruneri G**, Viale A, Bertolini F. Spontaneous cell fusion of acute leukemia cells and macrophages observed in cells with leukemic potential. Neoplasia. 2012;14(11):1057-66.
80. Montagna E, Maisonneuve P, Rotmensz N, Cancello G, Iorfida M, Balduzzi A, Galimberti V, Veronesi P, Luini A, **Pruneri G**, Bottiglieri L, Mastropasqua MG, Goldhirsch A, Viale G, Colleoni M. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer. 2013;13(1):31-9.
81. Maffini F, **Pruneri G**, Colombo N, Ansarin M, Grosso E, Bruschini R, Calabrese L, Chiesa F, Cipolla C, Pelosi G, Viale G. Metastasis to the right stellate ganglion and vagal nerve: pathological alterations causing sudden death. A case report. Acta Otorhinolaryngol Ital. 2012;32(4):263-5.
82. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, **Pruneri G**, Montagna E, Iorfida M, Mazza M, Balduzzi A, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol. 2013;24(3):661-8.
83. Bonanni B, Puntoni M, Cazzaniga M, **Pruneri G**, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol. 2012;30(21):2593-600.
84. Munzone E, Botteri E, Esposito A, Sciandivasci A, Franchi D, **Pruneri G**, Rotmensz N, Curigliano G, Adamoli L, Bocciolone L, Goldhirsch A, Nolé F. Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases. Ann Oncol. 2012 Nov;23(11):2884-90.
85. DeCensi A, **Pruneri G**, Guerrieri-Gonzaga A. Estrogen receptor in breast ductal carcinoma in situ: good cop, bad cop? J Clin Oncol. 2012;30(12):1384-6.
86. Fumagalli C, **Pruneri G**, Possanzini P, Manzotti M, Barile M, Feroce I, Colleoni M, Bonanni B, Maisonneuve P, Radice P, Viale G, Barberis M. Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. Breast Cancer Res Treat. 2012;134(1):131-7.
87. Azim HA Jr, Botteri E, Renne G, Dell'Orto P, Rotmensz N, Gentilini O, Sangalli C, **Pruneri G**, Di Nubila B, Locatelli M, Sotiriou C, Piccart M, Goldhirsch A, Viale G, Peccatori FA. The biological features and prognosis of breast cancer diagnosed during pregnancy: a case-control study. Acta Oncol. 2012 May;51(5):653-61. doi: 10.3109/0284186X.2011.636069.
88. **Early Breast Cancer Trialists' Collaborative Group (EBCTCG)**, Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432-44.
89. **Early Breast Cancer Trialists' Collaborative Group (EBCTCG)**, Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto REffect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.. Lancet. 2011;378(9804):1707-16
90. **Early Breast Cancer Trialists' Collaborative Group (EBCTCG)**, Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Lancet.Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. 2011;378(9793):771-84
91. Martin-Padura I, Gregato G, Marighetti P, Mancuso P, Calleri A, Corsini C, **Pruneri G**, Manzotti M, Lohsiriwat V, Rietjens M, Petit JY, Bertolini F. The white adipose tissue used in lipotransfer procedures is a rich reservoir of CD34+ progenitors able to promote cancer progression. Cancer Res. 2012;72(1):325-34.
92. Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua MG, Luini A, Veronesi P, Intra M, Montagna E, Cancello G, Cardillo A, Mazza M, Perri G, Iorfida M, **Pruneri G**, Goldhirsch A, Viale G. Outcome of special types of luminal breast cancer. Ann Oncol. 2012 Jun;23(6):1428-36
93. Cesinaro AM, Maiorana A, Ficarra G, **Pruneri G**. Metaplastic carcinoma with extensive dendritic cell differentiation: a previously unrecognised type of triple-negative breast cancer. Ann Oncol. 2011;22(11):2531-2.
94. Decensi A, Puntoni M, **Pruneri G**, Guerrieri-Gonzaga A, Lazzeroni M, Serrano D, Macis D, Johansson H, Pala O, Luini A, Veronesi P, Galimberti V, Dotti MC, Viale G, Bonanni B. Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.Cancer Prev Res (Phila). 2011;4(8):1181-9.
95. Martinelli P, Bonetti P, Sironi C, **Pruneri G**, Fumagalli C, Raviele PR, Volorio S, Pileri S, Chiarle R, McDuff FK, Tusi BK, Turner SD, Inghirami G, Pelicci PG, Colombo E. The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. Blood. 2011;117(24):6617-26.
96. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, **Pruneri G**, Montagna E, Dellapasqua S, Iorfida M, Cardillo A, Veronesi P, Luini A, Intra M, Gentilini O, Scarano E, Goldhirsch A, Colleoni M. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by

immunohistochemically selected subtypes. Breast Cancer Res Treat. 2011 Jun;127(3):713-20. doi: 10.1007/s10549-011-1465-7. Epub 2011 Mar 31. PubMed PMID: 21452022.

97. Rinaldi A, Ponzoni M, Uccella S, Rossi D, Gaidano G, Facchetti F, **Pruneri G**, Tibiletti MG, Capella C, Zucca E, Doglioni C, Catapano C, Bertoni F. In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas. Hematol Oncol. 2011;29(3):164-6.
98. Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, Locatelli M, **Pruneri G**, Giudici S, Bellomi M, Della Vigna P, Monfardini L, Orsi F, Nolè F, Munzone E, Goldhirsch A. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol. 2011;22(10):2227-33.
99. Laszlo D, **Pruneri G**, Andreola G, Radice D, Calabrese L, Rafaniello PR, Nassi L, Sammassimo S, Alietti A, Agazzi A, Vanazzi A, Martinelli G. Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin? Int J Surg Pathol. 2011 Aug;19(4):417-24.
100. DeCensi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S, Johansson H, Lien EA, **Pruneri G**, Viale G, Bonanni B. Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol. 2011;22(3):582-7.
101. Occhionorelli M, Santoro F, Pallavicini I, Gruszka A, Moretti S, Bossi D, Viale A, Shing D, Ronzoni S, Muradore I, Soncini M, **Pruneri G**, Rafaniello P, Viale G, Pelicci PG, Minucci S. The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha. Leukemia. 2011;25(5):814-20.
102. Saini KS, Azim HA Jr, Cocorocchio E, Vanazzi A, Saini ML, Raviele PR, **Pruneri G**, Peccatori FA. Rituximab in Hodgkin lymphoma: is the target always a hit? Cancer Treat Rev. 2011;37(5):385-90.
103. Mancuso P, Calleri A, Antoniotti P, Quarna J, **Pruneri G**, Bertolini F. If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. BMC Cancer. 2010;24;10:644.
104. Scandurra M, Mian M, Greiner TC, Rancoita PM, De Campos CP, Chan WC, Vose JM, Chigrinova E, Inghirami G, Chiappella A, Baldini L, Ponzoni M, Ferreri AJ, Franceschetti S, Gaidano G, Montes-Moreno S, Piris MA, Facchetti F, Tucci A, Nomdedeu JF, Lazure T, Lambotte O, Uccella S, Pinotti G, **Pruneri G**, Martinelli G, Young KH, Tibiletti MG, Rinaldi A, Zucca E, Kwee I, Bertoni F. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. Br J Haematol. 2010;151(3):221-31.
105. Montagna E, Bagnardi V, Rotmensz N, Viale G, **Pruneri G**, Veronesi P, Cancello G, Balduzzi A, Dellapasqua S, Cardillo A, Luini A, Zurrida S, Gentilini O, Mastropasqua MG, Bottiglieri L, Iorfida M, Goldhirsch A, Colleoni M. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat. 2010;124(3):689-99.
106. Bertazzoni P, Rabascio C, Gigli F, Calabrese L, Radice D, Calleri A, Gregato G, Negri M, Liptrott SJ, Bassi S, Nassi L, Sammassimo S, Laszlo D, Preda L, **Pruneri G**, Orlando L, Martinelli G. Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients. Leuk Lymphoma. 2010;51(8):1485-93.
107. Gruszka AM, Lavorgna S, Consalvo MI, Ottone T, Martinelli C, Cinquanta M,Ossolengo G, **Pruneri G**, Buccisano F, Divona M, Cedrone M, Ammatuna E, Venditti A, de Marco A, Lo-Coco F, Pelicci PG. A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias. Blood. 2010;116(12):2096-102.
108. Chigrinova E, Kwee I, Rinaldi A, Poretti G, **Pruneri G**, Neri A, Gaidano G, Ponzoni M, Zucca E, Bertoni F. Non-negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms. Br J Haematol. 2010;150(2):229-32.
109. Ponzoni M, Uccella S, Mian M, Rinaldi A, Facchetti F, **Pruneri G**, Gaidano G, Capella C, Zucca E, Doglioni C, Bertoni F. Syk expression patterns differ among B-cell lymphomas. Leuk Res. 2010;34(9):e243-5.
110. Laszlo D, Andreola G, Rigacci L, Fabbri A, Rabascio C, Mancuso P, **Pruneri G**, Radice D, Pinto A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol. 2010;28(13):2233-8.
111. Petrella F, **Pruneri G**, Ghioni M, Borri A, Galetta D, Gasparri R, Solli P, Veronesi G, Spaggiari L. Synchronous primary lung cancer, breast cancer recurrence, and mediastinal silicon-induced lymphadenitis. J Thorac Oncol. 2010;5(4):560-1.
112. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, **Pruneri G**, Veronesi P, Torrisi R, Montagna E, Luini A, Intra M, Gentilini O, Ghisini R, Goldhirsch A, Colleoni M. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol. 2010 Oct;21(10):1974-81.
113. Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, Cutuli B, **Pruneri G**, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010 Apr 20;28(12):2114-22.

114. Cocorocchio E, Vanazzi A, Bassi S, Peccatori F, Antoniotti P, Gigli F, Travaini L, Piperno G, **Pruneri G**, Preda L, Biffi R, Botteri E, Negri M, Martinelli G. Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma. Ecancermedicalscience. 2010;4:184.
115. Chiappa A, Bertani E, Makuuchi M, Zbar AP, Contino G, Viale G, **Pruneri G**, Bellomi M, Della Vigna P, Zampino MG, Fazio N, Travaini ML, Trifirò G, Corbellini C, Andreoni B. Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases. Hepatogastroenterology. 2009;829-34.
116. Martinelli G, Ryan G, Seymour JF, Nassi L, Steffanoni S, Alietti A, Calabrese L, **Pruneri G**, Santoro L, Kuper-Hommel M, Tsang R, Zinzani PL, Taghian A, Zucca E, Cavalli F. Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. Ann Oncol. 2009;20(12):1993-9.
117. Montagna E, Viale G, Rotmensz N, Maisonneuve P, Galimberti V, Luini A, Intra M, Veronesi P, Mazzarol G, **Pruneri G**, Renne G, Torrisi R, Cardillo A, Cancello G, Goldhirsch A, Colleoni M. Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. Breast Cancer Res Treat. 2009;118(2):385-94.
118. Rizzo S, Preda L, Villa G, Brambilla S, **Pruneri G**, Alietti A, Cassano E, Martinelli G, Bellomi M. Magnetic resonance imaging of primary breast lymphoma.Radiol Med. 2009;114(6):915-24.
119. Peccatori FA, Azim HA Jr, **Pruneri G**, Piperno G, Raviele PR, Preda L, Ciocca M, Orecchia R, Martinelli G. Management of anaplastic large-cell lymphoma during pregnancy. J Clin Oncol. 2009;27(25):e75-7.
120. Martinelli G, Gigli F, Calabrese L, Ferrucci PF, Zucca E, Crosta C, **Pruneri G**, Preda L, Piperno G, Gospodarowicz M, Cavalli F, Moreno Gomez H. Early stage gastric diffuse large B-cell lymphomas: results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. (IELSG 4). [corrected]. Leuk Lymphoma. 2009;50(6):925-31.
121. Mook S, Bonnefoi H, **Pruneri G**, Larsimont D, Jaskiewicz J, Sabadell MD, Macgrogan G, Van't Veer LJ, Cardoso F, Rutgers EJ. Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. Eur J Cancer. 2009;45(7):1201-8.
122. Colleoni M, Bagnardi V, Rotmensz N, Dellapasqua S, Viale G, **Pruneri G**, Veronesi P, Torrisi R, Luini A, Intra M, Galimberti V, Montagna E, Goldhirsch A. A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. Ann Oncol. 2009;20(7):1178-84.
123. Ottaviani F, Capaccio P, Villani F, Banderali M, **Pruneri G**, Klinger M, Pignataro L. Bona fide primary Merkel cell carcinoma of an intraparotid lymphnode in a HIV-positive patient. Int J Surg Pathol. 2010;18(5):406-8.
124. Tibiletti MG, Martin V, Bernasconi B, Del Curto B, Pecciarini L, Uccella S, **Pruneri G**, Ponzoni M, Mazzucchelli L, Martinelli G, Ferreri AJ, Pinotti G, Assanelli A, Scandurra M, Doglioni C, Zucca E, Capella C, Bertoni F. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Hum Pathol. 2009;40(5):645-52.
125. Agazzi A, Sammassimo S, Laszlo D, Liptrott S, Cascio R, Alietti A, Rabascio C, Mancuso P, **Pruneri G**, Martinelli G. Is there a role for 'modified VAD' in the treatment of multiple myeloma? Ecancermedicalscience. 2009;3:136.
126. De Cicco L, Vavassori A, Jereczek-Fossa BA, **Pruneri G**, Catalano G, Ferrari AM, Orecchia R. Lymph node metastases of Merkel cell carcinoma from unknown primary site: report of three cases. Tumori. 2008;94(5):758-61.
127. Froio E, D'Adda T, Fellegara G, Martella E, Caruana P, **Pruneri G**, Pesci A, Rindi G. Uterine carcinosarcoma metastatic to the lung as large-cell neuroendocrine carcinoma with synchronous sarcoid granulomatosis. Lung Cancer. 2009;64(3):371-7.
128. Azim HA Jr, **Pruneri G**, Cocorocchio E, Cinieri S, Raviele PR, Bassi S, Preda L, Martinelli G, Peccatori FA. Rituximab in lymphocyte-predominant Hodgkin disease. Oncology. 2009;76(1):26-9.
129. Colleoni M, Bagnardi V, Rotmensz N, Gelber RD, Viale G, **Pruneri G**, Veronesi P, Torrisi R, Cardillo A, Montagna E, Campagnoli E, Luini A, Intra M, Galimberti V, Scarano E, Peruzzotti G, Goldhirsch A. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat. 2009;116(2):359-69.
130. Rafaniello Raviele P, **Pruneri G**, Maiorano E. Plasmablastic lymphoma: a review. Oral Dis. 2009;15(1):38-45.
131. Chiappa A, Bertani E, Biffi R, Zbar AP, Viale G, **Pruneri G**, Bellomi M, Venturino M, Andreoni B. Effectiveness of LigaSure diathermy coagulation in liver surgery. Surg Technol Int. 2008;17:33-8.
132. Azim HA Jr, Gigli F, **Pruneri G**, Martinelli G, Travaini LL, Petralia G, Peccatori FA. Extramedullary myeloid sarcoma of the breast. J Clin Oncol. 2008;26(24):4041-3.
133. Agliano A, Martin-Padura I, Mancuso P, Marighetti P, Rabascio C, **Pruneri G**, Shultz LD, Bertolini F. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer. 2008;123(9):2222-7.

134. Mook S, Schmidt MK, Viale G, **Pruneri G**, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, Van't Veer LJ. TRANSBIG Consortium. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat. 2009;116(2):295-302.
135. **Pruneri G**, Alietti A, Agnelli L, Morabito F, Laszlo D, Calabrese L, Fabris S, Bertolini F, Agazzi A, Bottiglieri L, Raviele PR, Baldini L, Pileri S, Sabattini E, Bosari S, Maisonneuve P, Lambertenghi-Deliliers G, Bertoni F, Martinelli G, Viale G, Neri A. Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. Leuk Res. 2008 Oct;32(10):1628-32.
136. Trovato C, Sonzogni A, Ravizza D, **Pruneri G**, Rossi M, de Roberto G, Tamayo D, Vanazzi A, Fiori G, Crosta C. Confocal laser endomicroscopy diagnosis of gastric adenocarcinoma in a patient treated for gastric diffuse large-B-cell lymphoma. Dig Liver Dis. 2009;41(6):447-9.
137. Chiappa A, Zbar AP, Bertani E, Pace U, Viale G, **Pruneri G**, Venturino M, Zampino M, Fazio N, Bonomo G, Misitano P, Andreoni B. The Ligasure vessel sealer in liver resection: a pilot study. Hepatogastroenterology. 2007;54(80):2353-7.
138. Ferrucci PF, Vanazzi A, Crosta C, **Pruneri G**, Grana C, Bartolomei M, Paganelli G, Martinelli G. Efficacy of 90Y ibritumomab-tiuxetan treatment in a case of resistant gastric MALT non-Hodgkin's lymphoma. Ecancermedicalscience. 2008;2:79.
139. Ryan G, Martinelli G, Kuper-Hommel M, Tsang R, **Pruneri G**, Yuen K, Roos D, Lennard A, Devizzi L, Crabb S, Hossfeld D, Pratt G, Dell'Olio M, Choo SP, Bociek RG, Radford J, Lade S, Gianni AM, Zucca E, Cavalli F, Seymour JF; International Extranodal Lymphoma Study Group. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol. 2008;19(2):233-41.
140. Azim HA Jr, **Pruneri G**, Raviele PR, Steffanoni S, Martinelli G, Peccatori FA. ERCC1 Expression in Diffuse Large B-Cell Lymphoma Patients Treated with a Cisplatin-Based Regimen: A Brief Communication. J Egypt Natl Canc Inst. 2007;19(3):176-7.
141. Colleoni M, Rotmensz N, Maisonneuve P, Sonzogni A, **Pruneri G**, Casadio C, Luini A, Veronesi P, Intra M, Galimberti V, Torrisi R, Andrighetto S, Ghisini R, Goldhirsch A, Viale G. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol. 2007;18(10):1632-40.
142. Torrisi R, Bagnardi V, **Pruneri G**, Ghisini R, Bottiglieri L, Magni E, Veronesi P, D'Alessandro C, Luini A, Dellapasqua S, Viale G, Goldhirsch A, Colleoni M. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer. 2007;97(6):802-8.
143. De Pas T, Spitaleri G, **Pruneri G**, Curigliano G, Noberasco C, Luini A, Andreoni B, Testori A, de Braud F. Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases. Crit Rev Oncol Hematol. 2008;65(1):1-7.
144. Rocca A, Viale G, Gelber RD, Bottiglieri L, Gelber S, **Pruneri G**, Ghisini R, Balduzzi A, Pietri E, D'Alessandro C, Goldhirsch A, Colleoni M. Pathologiccomplete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. Cancer Chemother Pharmacol. 2008;61(6):965-71.
145. Tibiletti MG, Milani K, Martin V, Zucca E, Motta T, Cortelazzo S, Pinotti G, Mazzucchelli L, **Pruneri G**, Martinelli G, Barbazza R, Capella C, Bertoni F; International Extranodal Lymphoma Study Group (IELSG). Chromosome instability and translocation t(11;18) in primary gastric marginal zone B-cell lymphoma of MALT-type. Hematol Oncol. 2007;25(4):184-8.
146. Chiappa A, Zbar AP, Biffi R, Bertani E, Pace U, **Pruneri G**, Della Vigna P, Grassi C, Valerio M, Poldi D, Andreoni B. Prognostic factors and outcome of resected patients for gastrointestinal stromal tumors. Hepatogastroenterology. 2007;54(75):693-6.
147. Chiappa A, Biffi R, Zbar AP, Bertani E, Luca F, Pace U, Biella F, Grassi C, Zampino G, Fazio N, **Pruneri G,** Poldi D, Venturino M, Andreoni B. The influence of type of operation for distal rectal cancer: survival, outcomes, and recurrence. Hepatogastroenterology. 2007;54(74):400-6.
148. Laszlo D, Rabascio C, Andreola G, **Pruneri G**, Raia V, Calabrese L, Radice D, Saronni L, Martinelli G. Chlorambucil - rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: a clinical and biological analysis. Leuk Lymphoma. 2007;48(2):437-8.
149. Chiappa A, Bertani E, Biffi R, Pace U, Viale G, **Pruneri G**, Zampino G, Fazio N, Orsi F, Bonomo G, Monfardini L, Vigna PD, Andreoni B. Resection of colorectal liver metastases following neoadjuvant chemotherapy. Ecancermedicalscience. 2007;1:58.
150. Chiappa A, Zbar AP, Innis M, Garriques S, Bertani E, Biffi R, **Pruneri G**, Luzzato F, Vigna PD, Trovato C, Andreoni B. Prognostic factors affecting servival after surgical resection of gastrointestinal stromal tumours: a two-unit experience over 10 years. World J Surg Oncol. 2006;4:73.
151. Chiappa A, Biffi R, Bertani E, Zbar AP, Pace U, Crotti C, Biella F, Viale G, Orecchia R, **Pruneri G**, Poldi D, Andreoni B. Surgical outcomes after total mesorectal excision for rectal cancer. J Surg Oncol. 2006;94(3):182-93;discussion 181.

152. Gatti G, **Pruneri G**, Gilardi D, Brenelli F, Bassani G, Luini A. Report on a case of pure cribriform carcinoma of the breast with internal mammary node metastasis: description of the case and review of the literature. Tumori. 2006;92(3):241-3.Review.
153. Rinaldi A, Kwee I, Poretti G, Mensah A, **Pruneri G**, Capello D, Rossi D, Zucca E, Ponzoni M, Catapano C, Tibiletti MG, Paulli M, Gaidano G, Bertoni F. Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. Br J Haematol. 2006;134(1):27-36.
154. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Orlando L, Ghisini R, Viale G, **Pruneri G**, Veronesi P, Luini A, Intra M, Cardillo A, Torrisi R, Rocca A, Goldhirsch A. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol. 2006;17(10):1497-503.
155. Chiappa A, Zbar AP, Biffi R, Bertani E, Biella F, Viale G, Pace U, **Pruneri G**, Orecchia R, Lazzari R, Poldi D, Andreoni B. Effect of resection and outcome in patients with retroperitoneal sarcoma. ANZ J Surg. 2006 Jun;76(6):462-6. Erratum in: ANZ J Surg. 2008;97(6):560.
156. Diaz Brito JA, Gatti G, Vento AR, Galimberti V, Intra M, De Almeida RC, **Pruneri G**, Luini A. Report on a case of breast sarcoma metastatic to the axillary lymph nodes. Tumori. 2006;92(2):188-90.
157. **Pruneri G**, Ponzoni M, Ferreri AJ, Freschi M, Tresoldi M, Baldini L, Mattioli M, Agnelli L, Govi S, Mancuso P, Agazzi A, Bertolini F, Peccatori J, Bosari S, Gianelli U, Viale G, Neri A. The prevalence and clinical implications of c-kit expression in plasma cell myeloma. Histopathology. 2006;48(5):529-35.
158. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, **Pruneri G**, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, Bertolini F. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood. 2006;108(2):452-9.
159. Colombo E, Martinelli P, Zamponi R, Shing DC, Bonetti P, Luzi L, Volorio S, Bernard L, **Pruneri G**, Alcalay M, Pelicci PG. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res. 2006;66(6):3044-50.
160. Rinaldi A, Kwee I, Taborelli M, Largo C, Uccella S, Martin V, Poretti G, Gaidano G, Calabrese G, Martinelli G, Baldini L, **Pruneri G**, Capella C, Zucca E, Cotter FE, Cigudosa JC, Catapano CV, Tibiletti MG, Bertoni F. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol. 2006;132(3):303-16.
161. **Pruneri G**, Valentini S, Bertolini F, Del Curto B, Maiorano E, Viale G. SP4, a novel anti-cyclin D1 rabbit monoclonal antibody, is a highly sensitive probe for identifying mantle cell lymphomas bearing the t(11;14)(q13;q32) translocation. Appl Immunohistochem Mol Morphol. 2005;13(4):318-22.
162. Chiappa A, Zbar AP, Bertani E, Biffi R, Luca F, Pace U, Viale G, **Pruneri G**, Orecchia R, Lazzari R, Biella F, Grassi C, Zampino G, Fazio N, Della Vigna P, Andreoni L, Andreoni B. Surgical treatment of advanced colorectal cancer in the elderly. Chir Ital. 2005;57(5):589-96.
163. Pignataro L, Sambataro G, Pagani D, **Pruneri G**. Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review. Acta Otorhinolaryngol Ital. 2005 Apr;25(2):75-85. Review. Erratum in: Acta Otorhinolaryngol Ital. 2005;25(3):following 207.
164. Cortelezzi A, Fracchiolla NS, Mazzeo LM, Silvestris I, Pomati M, Somalvico F, Bertolini F, Mancuso P, **Pruneri G**, Gianelli U, Pasquini MC, Cortiana M, Deliliers GL. Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. Leuk Lymphoma. 2005;46(9):1345-51.
165. Ronchetti D, Arisi E, Neri A, **Pruneri G**, Digiuni B, Sambataro G, Gallo O, Pignataro L. Microsatellite analyses of recurrence or second primary tumor in head and neck cancer. Anticancer Res. 2005;25(4):2771-5.
166. **Pruneri G**, Fabris S, Dell'Orto P, Biasi MO, Valentini S, Del Curto B, Laszlo D, Cattaneo L, Fasani R, Rossini L, Manzotti M, Bertolini F, Martinelli G, Neri A, Viale G. The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. J Pathol. 2005;206(3):337-45.
167. Mastropasqua MG, Maiorano E, **Pruneri G**, Orvieto E, Mazzarol G, Vento AR, Viale G. Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. Mod Pathol. 2005;18(10):1277-82.
168. Luzzatto F, **Pruneri G**, Benini E, Manzotti M, Laszlo D, Martinelli G, Viale G. Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres and a high content of EBV-infected large B-cells carrying IgH chain gene monoclonal rearrangement. Histopathology. 2005;46(4):464-6.
169. Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S, Verdelli D, Intini D, Nobili L, Cro L, **Pruneri G**, Callea V, Stelitano C, Maiolo AT, Lombardi L, Neri A. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene. 2005;24(15):2461-73.
170. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Mazzarol G, **Pruneri G**, Luini A, Intra M, Veronesi P, Galimberti V, Torrisi R, Cardillo A, Goldhirsch A, Viale G. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol. 2005;23(7):1379-89.

171. Martone T, Rosso P, Albera R, Migliaretti G, Fraire F, Pignataro L, **Pruneri G**, Bellone G, Cortesina G. Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome. Oral Oncol. 2005;41(2):147-55.
172. Arisi E, **Pruneri G**, Carboni N, Sambataro G, Pignataro L. Prognostic significance of P27 and cyclin D1 co-expression in laryngeal squamous cell carcinoma: possible target for novel therapeutic strategies. J Chemother. 2004;16 Suppl 5:3-6.
173. **Pruneri G**, Pignataro L, Valentini S, Fabris S, Maisonneuve P, Carboni N, Pece S, Capra M, Del Curto B, Neri A, Viale G. Cyclin D3 immunoreactivity is an independent predictor of survival in laryngeal squamous cell carcinoma. Clin Cancer Res. 2005;11(1):242-8.
174. Martinelli G, Laszlo D, Ferreri AJ, **Pruneri G**, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005;23(9):1979-83.
175. Viale G, Maiorano E, **Pruneri G**, Mastropasqua MG, Valentini S, Galimberti V, Zurrida S, Maisonneuve P, Paganelli G, Mazzarol G. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg. 2005;241(2):319-25.
176. **Pruneri G**, Cinieri S, Peccatori F, Viale G. Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: Case 2. Plasma cell myeloma coexisting with metastatic breast carcinoma in the bone marrow. J Clin Oncol. 2005;23(1):232-3.
177. Viale G, Zurrida S, Maiorano E, Mazzarol G, **Pruneri G**, Paganelli G, Maisonneuve P, Veronesi U. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer. 2005;103(3):492-500.
178. Chiappa A, Biffi R, Zbar AP, Luca F, Crotti C, Bertani E, Biella F, Zampino G, Orecchia R, Fazio N, Venturino M, Crosta C, **Pruneri G**, Grassi C, Andreoni B. Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994-2003. Int J Colorectal Dis. 2005;20(3):221-30.
179. Colleoni M, Viale G, Zahrieh D, **Pruneri G**, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nolè F, Peruzzotti G, Goldhirsch A. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res. 2004;10(19):6622-8.
180. **Pruneri G**, Valentini S, Fabris S, Del Curto B, Laszlo D, Bertolini F, Martinelli G, Leocata P, Viale G, Neri A. Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index. Int J Cancer. 2004;112(1):71-7.
181. Ponzoni M, Savage DG, Ferreri AJ, **Pruneri G**, Viale G, Servida P, Bertolini F, Orazi A. Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining. Mod Pathol. 2004;17(12):1513-20.
182. Rabascio C, Muratori E, Mancuso P, Calleri A, Raia V, Foutz T, Cinieri S, Veronesi G, **Pruneri G**, Lampertico P, Iavarone M, Martinelli G, Goldhirsch A, Bertolini F. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res. 2004;64(12):4373-7.
183. Martinelli G, Cocorocchio E, Peccatori F, Zucca E, Saletti PC, Calabrese L, Pastano R, **Pruneri G**, Mazzetta C, Ghielmini M, Cavalli F. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis. Br J Haematol. 2004;125(5):584-9.
184. Laszlo D, Agazzi A, Goldhirsch A, Cinieri S, Bertolini F, Rabascio C, **Pruneri G**, Calabrese L, Cocquio A, Martinelli G. Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. Eur J Haematol. 2004;72(4):264-7.
185. Ronchetti D, Neglia CB, Cesana BM, Carboni N, Neri A, **Pruneri G**, Pignataro L. Association between p53 gene mutations and tobacco and alcohol exposure in laryngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2004;130(3):303-6.
186. Viale G, Sonzogni A, **Pruneri G**, Maffini F, Masullo M, Dell'Orto P, Mazzarol G. Histopathologic examination of axillary sentinel lymph nodes in breast carcinoma patients. J Surg Oncol. 2004;85(3):123-8. Review.
187. Insinga A, Monestiroli S, Ronzoni S, Carbone R, Pearson M, **Pruneri G**, Viale G, Appella E, Pelicci P, Minucci S. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J. 2004;23(5):1144-54.
188. Mastropasqua MG, **Pruneri G**, Renne G, De Cobelli O, Viale G. Basaloid cell carcinoma of the prostate. Virchows Arch. 2003;443(6):787-91. Review.
189. Morandi L, Pession A, Marucci GL, Foschini MP, **Pruneri G**, Viale G, Eusebi V. Intraepidermal cells of Paget's carcinoma of the breast can be genetically different from those of the underlying carcinoma. Hum Pathol. 2003;34(12):1321-30.

190. **Pruneri G**, Mazzarol G, Fabris S, Del Curto B, Bertolini F, Neri A, Viale G. Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation. Mod Pathol. 2003;16(9):886-92.
191. **Pruneri G**, Fabris S, Fasani R, Del Curto B, Capella C, Pozzi B, Motta T, Andreola S, Ferreri AJ, Ponzoni M, Viale G, Neri A. Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation. J Pathol. 2003;200(5):596-601.
192. Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, **Pruneri G**, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102(8):2741-5.
193. Ponzoni M, Ferreri AJ, **Pruneri G**, Pozzi B, Dell'Oro S, Pigni A, Pinotti G, Villa E, Freschi M, Viale G, Capella C. Prognostic value of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome. Int J Cancer. 2003;106(2):288-91.
194. Corsini C, Mancuso P, Paul S, Burlini A, Martinelli G, **Pruneri G**, Bertolini F. Stroma cells: a novel target of herceptin activity. Clin Cancer Res. 2003;9(5):1820-5.
195. Martinelli G, Agazzi A, Laszlo D, Santoro P, Mancuso P, **Pruneri G**, Greco P, Bertolini F. Idarubicin containing regimen in multiple myeloma: preliminary results of a pilot study using a modified "TANDEM" transplant program. Leuk Lymphoma. 2003;44(2):299-302.
196. Mancuso P, Calleri A, Cassi C, Gobbi A, Capillo M, **Pruneri G**, Martinelli G, Bertolini F. Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol. 2003;522:83-97.
197. Maiorano E, Mazzarol GM, **Pruneri G**, Mastropasqua MG, Zurrida S, Orvieto E, Viale G. Ectopic breast tissue as a possible cause of false-positive axillary sentinel lymph node biopsies. Am J Surg Pathol. 2003;27(4):513-8.
198. Intra M, Veronesi P, Mazzarol G, Galimberti V, Luini A, Sacchini V, Trifirò G, Gentilini O, **Pruneri G**, Naninato P, Torres F, Paganelli G, Viale G, Veronesi U. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg. 2003;138(3):309-13.
199. **Pruneri G**, Carboni N, Baldini L, Intini D, Colombi M, Bertolini F, Valentini S, Maisonneuve P, Viale G, Neri A. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation. Hum Pathol. 2003;34(1):41-7.
200. **Pruneri G**, Bertolini F, Baldini L, Valentini S, Goldaniga M, Soligo D, Carboni N, Viale G, Lambertenghi-Deliliers G. Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12. Br J Haematol. 2003;120(4):695-8.
201. **Pruneri G,** Fracchiolla N, Cortelezzi A, Ponzoni M, Maisonneuve P, Lambertenghi-Deliliers G. The prevalence and clinical relevance of p27 and cicli E immunoreactivity in myelodysplastic syndromes. Haematologica. 2003;88(1):109-10.
202. Capillo M, Mancuso P, Gobbi A, Monestiroli S, **Pruneri G**, Dell'Agnola C, Martinelli G, Shultz L, Bertolini F. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res. 2003;9(1):377-82.
203. Ronchetti D, Intini D, **Pruneri G**, Neri A, Pignataro L. Lack of Bcl10 gene mutations in laryngeal squamous cell carcinoma. J Laryngol Otol. 2002;116(8):610-2.
204. **Pruneri G**, Pignataro L, Manzotti M, Carboni N, Ronchetti D, Neri A, Cesana BM, Viale G. p63 in laryngeal squamous cell carcinoma: evidence for a role of TA-p63 down-regulation in tumorigenesis and lack of prognostic implications of p63 immunoreactivity. Lab Invest. 2002;82(10):1327-34.
205. Luini A, Gatti G, Frasson A, Naninato P, Magalotti C, Arnone P, Viale G, **Pruneri G**, Galimberti V, De Cicco C, Veronesi U. Sentinel lymph node biopsy performed with local anesthesia in patients with early-stage breast carcinoma. Arch Surg. 2002;137(10):1157-60.
206. Pelosi G, Pasini F, Olsen Stenholm C, Pastorino U, Maisonneuve P, Sonzogni A, Maffini F, **Pruneri G**, Fraggetta F, Cavallon A, Roz E, Iannucci A, Bresaola E, Viale G. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol. 2002;198(1):100-9.
207. **Pruneri G**, Masullo M, Renne G, Taccagni G, Manzotti M, Luini A, Viale G. Follicular dendritic cell sarcoma of the breast. Virchows Arch. 2002;441(2):194-9.
208. **Pruneri G**, Ponzoni M, Ferreri AJ, Decarli N, Tresoldi M, Raggi F, Baldessari C, Freschi M, Baldini L, Goldaniga M, Neri A, Carboni N, Bertolini F, Viale G. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol. 2002;118(3):817-20.
209. Dell'Agnola C, Rabascio C, Mancuso P, Capillo M, **Pruneri G**, Gobbi A, Minucci S, Ronzoni S, Volorio S, Calabrese L, Tradati N, Martinelli G, Shultz L, Bertolini F. In vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue. Exp Hematol. 2002;30(8):905-14.
210. Bertolini F, Dell'Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli S, Gobbi A, **Pruneri G**, Martinelli G. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res. 2002;62(11):3106-12.

211. Bertolini F, **Pruneri G**. Chimerism of the transplanted heart. N Engl J Med. 2002;346(18):1410-2; author reply 1410-2.
212. **Pruneri G**, Mazzarol G, Manzotti M, Viale G. Monoclonal proliferation of germinal center cells (incipient follicular lymphoma) in an axillary lymph node of a melanoma patient. Hum Pathol. 2001;32(12):1410-3.
213. Ferreri AJ, Ponzoni M, **Pruneri G**, Freschi M, Rossi R, Dell'Oro S, Baldini L, Buffa R, Carboni N, Villa E, Viale G. Immunoreactivity for p27(KIP1) and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma. Int J Cancer. 2001;94(4):599-604.
214. Viale G, Maiorano E, Mazzarol G, Zurrida S, Galimberti V, Luini A, Renne G, **Pruneri G**, Maisonneuve P, Veronesi U. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer. 2001;92(6):1378-84.
215. Monestiroli S, Mancuso P, Burlini A, **Pruneri G**, Dell'Agnola C, Gobbi A, Martinelli G, Bertolini F. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 2001;61(11):4341-4.
216. Mancuso P, Burlini A, **Pruneri G**, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood. 2001;97(11):3658-61.
217. Galimberti V, Zurrida S, Intra M, Monti S, Arnone P, **Pruneri G**, De Cicco C. Sentinel Node Biopsy Interpretation: The Milan Experience. Breast J. 2000;6(5):306-309.
218. Pignataro L, Carboni N, Midolo V, Bertolini F, Buffa R, Cesana BM, Neri A, Viale G, **Pruneri G**. Clinical relevance of microvessel density in laringea squamous cell carcinomas. Int J Cancer. 2001;92(5):666-70.
219. Vicentini L, Grossano L, **Pruneri G**, Roncaglia O. [Primary large B-cell lymphoma of the thyroid. Apropos of 2 cases]. Minerva Chir. 2000;55(7-8):545-8. Italian.
220. Bertolini F, Mancuso P, Gobbi A, **Pruneri G**. The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp Hematol. 2000;28(9):993-1000.
221. Bertolini F, Fusetti L, Rabascio C, Cinieri S, Martinelli G, **Pruneri G**. Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma. Leukemia. 2000;14(8):1477-82.
222. Bertolini F, Fusetti L, Mancuso P, Gobbi A, Corsini C, Ferrucci PF, Martinelli G, **Pruneri G**. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood. 2000;96(1):282-7.
223. Fusetti L, **Pruneri G**, Gobbi A, Rabascio C, Carboni N, Peccatori F, Martinelli G, Bertolini F. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. Cancer Res. 2000;60(9):2527-34.
224. **Pruneri G**, Fabris S, Baldini L, Carboni N, Zagano S, Colombi MA, Ciceri G, Lombardi L, Rocchi M, Buffa R, Maiolo AT, Neri A. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol. 2000;156(5):1505-13.
225. Capaccio P, **Pruneri G**, Carboni N, Pagliari AV, Quatela M, Cesana BM, Pignataro L. Cyclin D1 expression is predictive of occult metastases in head and neck cancer patients with clinically negative cervical lymph nodes. Head Neck. 2000;22(3):234-40.
226. **Pruneri G**, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, Buffa R, Lambertenghi-Deliliers G, Pezzella F. Angiogenesis in myelodysplastic syndromes. Br J Cancer. 1999;81(8):1398-401.
227. **Pruneri G**, Pignataro L, Carboni N, Buffa R, Di Finizio D, Cesana BM, Neri A. Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer. J Clin Oncol. 1999;17(10):3150-9.
228. Pignataro L, Capaccio P, **Pruneri G**, Carboni N, Buffa R, Neri A, Ottaviani A. The predictive value of p53, MDM-2, cyclin D1 and Ki67 in the progression from low-grade dysplasia towards carcinoma of the larynx. J Laryngol Otol. 1998;112(5):455-9.
229. Pignataro L, **Pruneri G**, Carboni N, Capaccio P, Cesana BM, Neri A, Buffa R. Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma. J Clin Oncol. 1998;16(9):3069-77.
230. Guddo F, Giatromanolaki A, Patriarca C, Hilkens J, Reina C, Alfano RM, Vignola AM, Koukourakis MI, Gambacorta M, **Pruneri G**, Coggi G, Bonsignore G. Depolarized expression of episialin (EMA, MUC1) in lung adenocarcinoma is associated with tumor progression. Anticancer Res. 1998;18(3B):1915-20.
231. **Pruneri G**, Pignataro L, Carboni N, Ronchetti D, Cesana BM, Ottaviani A, Neri A, Buffa R. Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma. Int J Cancer. 1998;79(3):263-8.
232. Pignataro L, Capaccio P, Carboni N, **Pruneri G**, Ottaviani A, Buffa R, Broich G. p53 and cyclinX D1 protein expression in carcinomas of the parotid gland. Anticancer Res. 1998;18(2B):1287-90.
233. **Pruneri G**, Graziadei G, Ermellino L, Baldini L, Neri A, Buffa R. Plasmablastic lymphoma of the stomach. A case report. Haematologica. 1998;83(1):87-9.
234. Graziadei G, **Pruneri G**, Carboni N, Luminari S, Targia ML, Neri A, Colombi M, Buffa R, Baldini L. Low-grade MALT lymphoma involving multiple mucosal sites and bone marrow. Ann Hematol. 1998;76(2):81-3.

235. **Pruneri G**, Galli S, Rossi RS, Roncalli M, Coggi G, Ferrari A, Simonato A, Siccardi AG, Carboni N, Buffa R. Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. Prostate. 1998;34(2):113-20.
236. **Pruneri G**, Pignataro L, Carboni N, Luminari S, Capaccio P, Neri A, Buffa R. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation. Mod Pathol. 1997;10(8):785-92.
237. Capaccio P, **Pruneri G**, Carboni N, Pagliari AV, Buffa R, Neri A, Ottaviani A, Pignataro L. Cyclin D1 protein expression is related to clinical progression in laryngeal squamous cell carcinomas. J Laryngol Otol. 1997;111(7):622-6.
238. Patriarca C, **Pruneri G**, Alfano RM, Carboni N, Ermellino L, Guddo F, Buffa R, Siccardi AG, Coggi G. Polysialylated N-CAM, chromogranin A and B, and secretogranin II in neuroendocrine tumours of the lung. Virchows Arch. 1997;430(6):455-60.
239. Pignataro L, Carboni N, Pagliari AV, Capaccio P, Ottaviani F, **Pruneri G**. Bcl-2 expression is related to poor differentiation and advanced clinical stage in laryngeal squamous cell carcinoma. J Chemother. 1997;9(2):115-6.
240. Capaccio P, Carboni N, Pignataro L, Scotti A, Ottaviani F, **Pruneri G**. Cyclin D1, p53, mdm2, and Ki67 protein expression in preneoplastic lesions of the larynx. J Chemother. 1997;9(2):113-4.
241. Fracchiolla NS, **Pruneri G**, Pignataro L, Carboni N, Capaccio P, Boletini A, Buffa R, Neri A. Molecular and immunohistochemical analysis of the bcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas: correlation of protein expression with lymph node metastases and advanced clinical stage. Cancer. 1997;79(6):1114-21.
242. Pignataro L, Capaccio P, **Pruneri G**, Carboni N, Fracchiolla N, Richelda R, Scaramellini G, Neri A, Buffa R. p53 and cyclin D1 protein expression in glottic laryngeal squamous cell carcinomas involving the anterior commissure (pT1bN0M0). Int J Oncol. 1996;9(3):553-7.
243. **Pruneri G**, Pignataro L, Fracchiolla NS, Ferrero S, Capaccio P, Carboni N, Ottaviani A, Maiolo AT, Neri A, Buffa R. p53 protein expression in laringea squamous cell carcinomas bearing wild-type and mutated p53 gene. Histopathology. 1996;28(6):513-9. PubMed PMID: 8803594.
244. Fogazzi GB, Carboni N, **Pruneri G**, Ponticelli C. The cells of the deep layers of the urothelium in the urine sediment: an overlooked marker of severe diseases of the excretory urinary system. Nephrol Dial Transplant. 1995;10(10):1918-9.
245. Ferrero S, Buffa R, **Pruneri G**, Siccardi AG, Pelagi M, Lee AK, Coggi G, Bosari S. The prevalence and clinical significance of chromogranin A and secretogranin II immunoreactivity in colorectal adenocarcinomas. Virchows Arch. 1995;426(6):587-92.

Data	4 Dicembre 2017	Luogo	Milano